ABCLAbCellera Biologics Inc.
Price
+178%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growing in the filings, the market undecided.
AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. We have built a platform for advancing antibody drug programs that we believe provides us with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities including multispecifics and antibody-drug conjugates.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
AbCellera Biologics Inc. (ABCL) reported revenue of $4.0M in Q2 2026 (quarter ended Jun 30, 2026), down 76% from the same quarter a year earlier. That came with net loss of $55M. For the full year FY2025, revenue was $75M (+161% year on year) and net income −$146M. Its largest product in Q2 2026 was Research Fees at $3.9M, 96% of the disclosed total, well ahead of Licensing And Royalty at 3.7%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 13, 2026On August 12, 2026, AbCellera Biologics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and J.P. Morgan Securities LLC as the representatives of the several underwriters (the “Underwriters”) relating to an underwritten public offering of (a) 17,435,897 …Material agreement entered · Form 8-K
- Aug 7, 2026On August 7, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing it will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause on Monday, August 10, 2026 and hold an investor conference call at 4:30 …Other event · Form 8-K
- Jul 29, 2026On July 29, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing a collaboration with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $4.0MThe company’s own SEC segment disclosure.
- Research Fees$3.9M96%
- Licensing And Royalty$149.0K4%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.